New drug BI 3031185 put to the test: safety check and birth control interaction study
NCT ID NCT07656792
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial investigates the safety and tolerability of a new drug called BI 3031185 in healthy Japanese men, given as single or multiple doses. It also examines whether multiple doses of BI 3031185 affect how the body processes a common oral contraceptive (YAZ®) in healthy Japanese women. The study aims to gather crucial safety data and understand potential drug interactions before moving to larger trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BI 3031185
What this could lead to
If successful, this could pave the way for future studies of BI 3031185 in treating diseases, by first confirming it is safe and does not interfere with common medications.
What could go wrong
This is an early phase 1 trial in healthy volunteers, not patients. The drug may prove unsafe or ineffective in later trials. Results may not apply to other populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fukuoka Mirai Hospital
Fukuoka, Fukuoka, 813-0017, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••